Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Sales | 41,097 | 50,561 | 47,167 | 66,725 | 82,757 |
| Gross Profit | 41,097 | 50,561 | 47,167 | 66,725 | 82,757 |
| Operating Expenses | 337,105 | 455,541 | 140,109 | 196,181 | 137,575 |
| Operating Income | -296,008 | -404,980 | -92,942 | -129,456 | -54,818 |
| Other Income | 5,935 | 4,376 | 1,022 | 12,870 | -2,831 |
| Pre-tax Income | -290,073 | -400,604 | -91,920 | -116,586 | -57,649 |
| Income Tax | N/A | -40,209 | -2,695 | -10,572 | 0 |
| Net Income Continuous | -290,073 | -360,395 | -89,225 | -106,014 | -57,649 |
| Net Income | $-290,073 | $-360,395 | $-89,225 | $-106,014 | $-57,649 |
| EPS Basic Total Ops | -3.45 | -4.85 | -1.45 | -2.11 | -1.36 |
| EPS Basic Continuous Ops | -3.45 | -4.85 | -1.45 | -2.11 | -1.36 |
| EPS Diluted Total Ops | -3.45 | -4.85 | -1.45 | -2.11 | -1.36 |
| EPS Diluted Continuous Ops | -3.45 | -4.85 | -1.45 | -2.11 | -1.36 |
| EBITDA(a) | $-276,958 | $-393,054 | $-82,713 | $-120,421 | $-49,693 |